ICEsoft to Host Investor Name to Current Q2 Monetary Outcomes and to Present a Common Enterprise Replace

Calgary, Alberta–(Newsfile Corp. – September 13, 2021) – ICEsoft Applied sciences Canada Corp. (CSE: ISFT), the “Company” or the “Firm” or “ICEsoft”, is happy to announce it will likely be internet hosting an upcoming investor name to current its Q2 monetary outcomes and to offer a normal enterprise replace. The decision is to be held on Monday, September 20, 2021 at 10:30 AM MST / 12:30 PM EST. Events eager about attending could accomplish that utilizing the next credentials.

Subject: ICEsoft Applied sciences Canada Corp. Traders Name
Date/Time: Monday, September 20, 2021 10:30 AM (MST)

Read More

IN8bio Reviews Second Quarter 2021 Monetary Outcomes and Offers Company Replace

  • First cohort dosing accomplished in Section 1 scientific trials of INB-200 and INB-100

  • Information shows made at ASCO and AACR

  • $40M preliminary public providing (IPO) in August 2021 to fund persevering with operations

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical firm centered on the invention and improvement of revolutionary gamma-delta T-cell therapies using its DeltEx platform, as we speak introduced monetary outcomes and operational highlights for the second quarter ended June 30, 2021. As well as, the Firm offered an summary of latest company developments.

“Within the

Read More

NANOBIOTIX Supplies Enterprise Replace and Stories Monetary Outcomes for the First Half of 2021

  • Constructive information from Examine 102 Enlargement reported in H1 2021 included an total goal response price of 82.5% and an entire response price of 62.5% in extremely susceptible, aged affected person inhabitants, offering continued assist for the deliberate initiation of a pivotal section III international registration examine in domestically superior head and neck squamous cell carcinoma in late This autumn 2021

  • Following constructive information from ongoing Examine 1100 introduced in H1 2021 exhibiting that NBTXR3 together with anti-PD-1 resulted in tumor regression in 76.9% of evaluable sufferers no matter prior anti-PD-1 publicity, Nanobiotix intends to

Read More